ASX:1AD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has AdAlta's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1AD is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: 1AD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.


Market Performance


7 Day Return

4.3%

1AD

-2.5%

AU Biotechs

0.5%

AU Market


1 Year Return

14.3%

1AD

5.7%

AU Biotechs

0.9%

AU Market

Return vs Industry: 1AD exceeded the Australian Biotechs industry which returned 7% over the past year.

Return vs Market: 1AD exceeded the Australian Market which returned 1% over the past year.


Shareholder returns

1ADIndustryMarket
7 Day4.3%-2.5%0.5%
30 Day4.3%2.0%9.3%
90 Day21.2%5.4%12.3%
1 Year16.4%14.3%6.7%5.7%4.3%0.9%
3 Year-44.9%-47.8%116.2%109.1%23.0%7.9%
5 Yearn/a208.3%189.7%59.8%27.5%

Long-Term Price Volatility Vs. Market

How volatile is AdAlta's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AdAlta undervalued compared to its fair value and its price relative to the market?

5.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1AD is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.

PE vs Market: 1AD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1AD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1AD is good value based on its PB Ratio (5.3x) compared to the AU Biotechs industry average (6.3x).


Next Steps

Future Growth

How is AdAlta forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

14.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1AD's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 1AD's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1AD's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if 1AD's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1AD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AdAlta performed over the past 5 years?

-31.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1AD is currently unprofitable.

Growing Profit Margin: 1AD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1AD is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.

Accelerating Growth: Unable to compare 1AD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1AD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9.3%).


Return on Equity

High ROE: 1AD has a negative Return on Equity (-162.25%), as it is currently unprofitable.


Next Steps

Financial Health

How is AdAlta's financial position?


Financial Position Analysis

Short Term Liabilities: 1AD's short term assets (A$6.7M) exceed its short term liabilities (A$3.2M).

Long Term Liabilities: 1AD has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 1AD's debt to equity ratio (59.2%) is considered high.

Reducing Debt: Insufficient data to determine if 1AD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1AD has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: 1AD is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is AdAlta current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1AD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1AD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1AD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1AD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1AD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Tim Oldham

1.17yrs

Tenure

AU$470,053

Compensation

Dr. Timothy Charles Oldham, also known as Tim, B.Sc (Hons), L.L.B. (Hons), Ph.D., has been Chief Executive Officer, Managing Director and Director of AdAlta Limited since October 8, 2019. Prior to this, he...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD349.82K) is about average for companies of similar size in the Australian market ($USD281.85K).

Compensation vs Earnings: Insufficient data to compare Tim's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Oldham
CEO, MD & Director1.17yrsAU$470.05k0.086%
A$ 24.3k
Dallas Hartman
Chief Operating Officer3.17yrsno datano data
Michael Foley
Chief Scientific Advisor & Chief Scientific Officerno datano datano data
Cameron Jones
Company Secretary3.58yrsno datano data

3.2yrs

Average Tenure

Experienced Management: 1AD's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Oldham
CEO, MD & Director1.17yrsAU$470.05k0.086%
A$ 24.3k
Michael Foley
Chief Scientific Advisor & Chief Scientific Officerno datano datano data
David Fuller
Non-Executive Director0.42yrno data0.076%
A$ 21.5k
Robert Peach
Independent Non-Executive Director4.08yrsAU$33.75k0.14%
A$ 38.3k
James Williams
Alternate Non-Executive Director0.75yrAU$33.75k0.51%
A$ 142.5k
Elizabeth McCall
Non-Executive Director10yrsAU$33.75k0.068%
A$ 19.2k
Paul Donald MacLeman
Non-Executive Chairmanno dataAU$77.96k0.19%
A$ 54.4k
Brian Richardson
Scientific Advisorno datano datano data
John Westwick
Scientific Advisorno datano datano data

1.2yrs

Average Tenure

55yo

Average Age

Experienced Board: 1AD's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1AD insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.2%.


Top Shareholders

Company Information

AdAlta Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AdAlta Limited
  • Ticker: 1AD
  • Exchange: ASX
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$28.195m
  • Shares outstanding: 245.18m
  • Website: https://adalta.com.au

Location

  • AdAlta Limited
  • 2 Park Drive
  • Unit 15
  • Bundoora
  • Victoria
  • 3083
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1ADASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2016
1ADCHIA (Chi-X Australia)YesOrdinary SharesAUAUDAug 2016

Biography

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company’s lead i-body drug candidate includes AD-214, which is in Phase I clinical tria...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 07:05
End of Day Share Price2020/12/04 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.